LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects

LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability... BioDrugs (2017) 31:349–355 DOI 10.1007/s40259-017-0230-9 ORIGINAL RESEARCH ARTICLE LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects 1,2 2 2 1,2 • • • • Heechan Lee Hyewon Chung SeungHwan Lee Howard Lee 3 2 2 2 • • • • Sung Mo Yang Seo Hyun Yoon Joo-Youn Cho In-Jin Jang Kyung-Sang Yu Published online: 27 May 2017 Springer International Publishing Switzerland 2017 Abstract and AUC of LBEC0101 to Enbrel were 1.02 inf Objectives We performed this study to compare the phar- (0.92–1.13) and 0.96 (0.87–1.05), respectively, which were macokinetic (PK), immunogenicity, and tolerability pro- within a conventional bioequivalence criteria of 0.80–1.25. files of etanercept between LBEC0101, a proposed ADA development was also comparable. Both drugs were biosimilar, and Enbrel , the reference biological product. well tolerated. Methods A randomized, double-blind, single-dose, two- Conclusions LBEC0101 showed similar PK, immuno- treatment, two-period, two-sequence, crossover study was genicity, and tolerability profiles to Enbrel after a single conducted in 48 healthy males. In each period, a single subcutaneous injection in healthy males. LBEC0101 can be dose of LBEC0101 or Enbrel was subcutaneously injec- further developed as a potential etanercept biosimilar ted http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects

Loading next page...
 
/lp/springer_journal/lbec0101-a-proposed-etanercept-biosimilar-pharmacokinetics-Ev5dtanaxc
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing Switzerland
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-017-0230-9
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial